Your browser doesn't support javascript.
Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group. / Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología.
Morollón, N; Belvís, R; De Dios, A; Pagès, N; González-Oria, C; Latorre, G; Santos-Lasaosa, S.
  • Morollón N; Unidad de Cefaleas y Neuralgias, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: noemimorollon@gmail.com.
  • Belvís R; Unidad de Cefaleas y Neuralgias, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
  • De Dios A; Servicio de Farmacia Hospitalaria, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
  • Pagès N; Servicio de Farmacia Hospitalaria, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
  • González-Oria C; Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario de Fuenlabrada, Madrid, España.
  • Latorre G; Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario Virgen del rocío, Sevilla, España.
  • Santos-Lasaosa S; Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa. Instituto de Investigación Sanitaria Aragón (IIS-Aragón), Zaragoza, España.
Neurologia (Engl Ed) ; 35(9): 628-632, 2020.
Article in English, Spanish | MEDLINE | ID: covidwho-747866
ABSTRACT

INTRODUCTION:

In recent months, doubts have arisen among patients, general practitioners, and neurologists as to whether some drugs commonly used in patients with headaches and neuralgia may favour or complicate the disease caused by SARS-CoV-2. MATERIAL AND

METHODS:

We collected information on the opinions of scientific societies and medicines agencies (American, European, and Spanish) to clarify doubts regarding the use of drugs such as lisinopril, candesartan, ibuprofen, corticosteroids, carbamazepine, and monoclonal antibodies targeting the calcitonin gene-related peptide in the context of the COVID-19 pandemic.

RESULTS:

We make recommendations about the use of standard headache treatments in the context of the COVID-19 pandemic, based on the current scientific evidence.

CONCLUSIONS:

At present, there is no robust scientific argument to formally contraindicate any of the standard treatments employed for headaches and neuralgias.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Headache / Analgesics / Neuralgia Type of study: Prognostic study Topics: Long Covid Language: English / Spanish Journal: Neurologia (Engl Ed) Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Headache / Analgesics / Neuralgia Type of study: Prognostic study Topics: Long Covid Language: English / Spanish Journal: Neurologia (Engl Ed) Year: 2020 Document Type: Article